GlassScriptPhysician profile
Kimberly Bunker
NPI 1669991287
$2,479.82
in general payments reported to CMS, 2019-2025
29 companies · $759 in 2025
The $759 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.26 · 2022: $281 · 2023: $669 · 2024: $705 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $282.45 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $274.61 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $199.40 | 2022-2023 | Padcev, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $181.42 | 2022-2025 | Iclusig, Ninlaro, Fruzaqla |
| Eisai INC. | $161.91 | 2022-2025 | |
| Genentech USA, INC. | $155.75 | 2023-2025 | Tecentriq, Alecensa, Rozlytrek |
| Servier Pharmaceuticals LLC | $141.17 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $107.20 | 2023-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $89.11 | 2022-2024 | |
| Amgen INC. | $88.32 | 2022-2023 | Lumakras |
| Pfizer INC. | $88.19 | 2024-2025 | |
| Exelixis INC. | $84.66 | 2024-2025 | Cabometyx |
| Daiichi Sankyo INC. | $74.02 | 2024-2025 | Enhertu |
| Incyte Corporation | $69.13 | 2023-2025 | Monjuvi, Pemazyre |
| Array Biopharma INC | $51.83 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.55 | 2025 | |
| Deciphera Pharmaceuticals INC. | $51.41 | 2024-2025 | Qinlock, Romvimza |
| Celgene Corporation | $43.34 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $41.43 | 2024-2025 | |
| Janssen Biotech, INC. | $37.86 | 2024-2025 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $34.62 | 2024-2025 | Tagrisso |
| Geron Corporation | $28.09 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $26.23 | 2025 | |
| Beigene USA, INC. | $22.68 | 2023 | Brukinsa |
| Menarini Silicon Biosystems, INC. | $22.59 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.20 | 2023 | Ultomiris |
| Lilly USA, LLC | $18.44 | 2025 | Retevmo, Jaypirca, Verzenio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Bunker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.